---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-132991"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T14:56:55.124061+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cellectar receives Nasdaq non-compliance notice; appoints Laurence Reilly as interim CMO

## Summary
- Received Nasdaq deficiency notice for bid price below $1 for 30 consecutive business days; has 180 days until May 2, 2022 to cure.
- Appointed Laurence Reilly as interim CMO effective Nov 2; John Friend departs for personal reasons after transition.
- Company asserts sufficient cash into 2H 2023; focused on iopofosine I-131 registrational trial in WM and other programs.
- Dr. Reilly previously consulted for Cellectar; experience at Pfizer and Avillion; will oversee clinical development.

## SEC filing metadata
- accession: 0001104659-21-132991
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/0001104659-21-132991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/tm2131707d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-132991
- JSON: https://secwatch.observer/filing/0001104659-21-132991.json
- Plain text: https://secwatch.observer/filing/0001104659-21-132991.txt

## Key facts
- Executive change
  John Friend departed as Chief Medical Officer at Cellectar Biosciences, Inc..
  - Action: stepping down
  - Role: Chief Medical Officer
  source text: Dr. Reilly succeeds John Friend, MD, who is stepping down but will stay on through mid-November to finalize the ongoing transition.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/0001104659-21-132991-index.htm
- Executive change
  Laurence Reilly was appointed as Interim Chief Medical Officer at Cellectar Biosciences, Inc..
  - Action: appointed
  - Role: Interim Chief Medical Officer
  source text: On November 2, 2021, the Company appointed Dr. Laurence Reilly as Interim Chief Medical Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465921132991/0001104659-21-132991-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.